Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
RESEARCH TOOLSreports
ENTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.71 - $17.80
Previous CloseN/A
Volume330.58K
Average Volume (3M)560.22K
Market Cap
$178.77M
Enterprise Value$126.11M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 12, 2025EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.95
Shares Outstanding21,332,544
10 Day Avg. Volume710,150
30 Day Avg. Volume560,218
Standard Deviation0.17
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.53
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.86
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$16.33Price Target Upside94.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Enanta Pharmaceuticals News
PremiumCompany Announcements
Enanta Pharmaceuticals Advances in Virology and Immunology
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement indicated they have sufficient cash runway into fiscal 2027 to achieve multiple key milestones across both their virology and immunology portfolios.
Partnership OpportunitiesManagement announced plans to evaluate potential partnership opportunities for advancing its RSV programs.
Study SuccessZelicapavir successfully met the study's primary virology endpoint in the pooled efficacy population with a peak viral load reduction compared to placebo.
Bears Say
Market PressureCombination of down-draft in biotech, mixed RSV news for zelicapavir, and possibly misplaced safety concerns may be pressuring ENTA shares unfairly.
Pipeline CreditCompany is given limited to no credit for its pipeline, including immunology programs.
Symptom Improvement ClarityAdded clarity is sought on zelicapavir's efficacy in symptom improvement for the pediatric population.
---
Ownership Overview
7.27% Insiders
14.75% Mutual Funds
22.71% Other Institutional Investors
43.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $4.71 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is $178.77M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is May 12, 2025 which is in 79 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.353 by $0.303.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -1.16.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,332,544 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.353. Following the earnings report the stock price went up 14.082%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in ENTA
---
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.33 (94.87% Upside)
$16.33 (94.87% Upside)
Insider Transactions
Bought Shares
Worth $129.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.48%
12-Months-Change
Fundamentals
Return on Equity
-69.10%
Trailing 12-Months
Asset Growth
-18.64%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Stock 12 Month Forecast
Average Price Target
$16.33
▲(94.87% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Gilead Sciences
―
Merck & Company
―
Vertex Pharmaceuticals
―
AbbVie
―
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+0.21%
reiterated a buy rating 10 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +0.21% per trade.
---